The small, virtual team at Syntimmune bags a $50M round in the march toward a pivotal test
With a pair of Phase Ib/IIa studies underway for its lead drug, the virtual team at Syntimmune now has a $50 million venture round— largely provided by Apple Tree Partners — to take them on toward a potential registration study.
Over the last 3-plus years since the biotech was founded, Syntimmune has been making steady progress on its key goal: working on drugs targeting IgG-mediated autoimmune diseases by blocking FcRn-IgG interactions. They’ve put the lead program for SYNT001 through a small Phase Ia and now they’re intent on extending their view into the potential efficacy their lead drug has in two rare diseases— pemphigus and warm autoimmune hemolytic anemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
